1-2 of 2
Stephen Mulligan
Close
Sort by
Journal Articles

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García-Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández De Larrea, David Belada, Edward Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1639–1650.
https://doi.org/10.1182/bloodadvances.2023010906
Published: 2024
Includes: Supplemental data
Journal Articles

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

Clinical Trials & Observations
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, Marek Trneny, Marzia Varettoni, Stephen Opat, Shirley D'Sa, Roger G. Owen, Gavin Cull, Stephen Mulligan, Jaroslaw Czyz, Jorge J. Castillo, Marina Motta, Tanya Siddiqi, Mercedes Gironella Mesa, Miquel Granell Gorrochategui, Dipti Talaulikar, Pier Luigi Zinzani, Elham Askari, Sebastian Grosicki, Albert Oriol, Simon Rule, Janusz Kloczko, Alessandra Tedeschi, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y. Chan, Jan Michel, Jingjing Schneider, Ziwen Tan, Aileen Cohen, Jane Huang, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2020) 4 (23): 6009–6018.
https://doi.org/10.1182/bloodadvances.2020003010
Published: 2020
Includes: Supplemental data